1583 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Lymphatic Diseases"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Conditions: Lymphedema;   Lymphatic Disorders;   Lipedema;   Vascular Malformation;   Vascular Anomaly
Intervention: Drug: NIRFLI with ICG
2 Recruiting National Lymphatic Disease and Lymphedema Registry
Condition: Lymphedema
3 Unknown  Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder;   Canale-Smith Syndrome
4 Not yet recruiting A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen
Condition: Lymphatic Diseases
Interventions: Drug: Brentuximab Vedotin;   Drug: Bendamustine
5 Recruiting Sildenafil for the Treatment of Lymphatic Malformations
Conditions: Lymphatic Malformations;   Lymphatic Diseases
Interventions: Drug: Sildenafil 20 mg tablets;   Other: Placebo tablets (resembling Revatio)
6 Recruiting Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Conditions: Lymphatic Diseases;   Hematopoietic Malignancy
Intervention: Biological: Umbilical Cord Blood (UCB)
7 Recruiting Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Conditions: Lymphangiomatosis;   Lymphedema;   Lymphangiectasia;   Pulmonary Lymphangiectasia
8 Recruiting Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Radiation: Yttrium Y 90 Ibritumomab tiuxetan;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Biological: Rituximab;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
9 Recruiting Study Evaluating Venetoclax in Subjects With Relapsed or Refractory Non-hodgkin Lymphoma or Multiple Myeloma
Conditions: Non-Hodgkin Lymphoma;   Multiple Myeloma
Intervention: Drug: venetoclax
10 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
11 Unknown  TREatment of degeNerative and Neoplastic Diseases With Rituximab
Condition: Diffuse Large B Cell Lymphoma
Intervention: Biological: Rituximab
12 Recruiting Bronchoscopic Sampling Techniques in Sarcoidosis
Conditions: Mediastinal Lymph Node Enlargement;   Sarcoidosis;   Tuberculosis;   Lymphomas
Interventions: Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB);   Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA);   Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes;   Procedure: Bronchoalveolar lavage (BAL);   Procedure: Endobronchial forceps biopsy
13 Unknown  Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy
Conditions: Lymphoma;   Kikuchi's Disease
14 Not yet recruiting A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCHNC), Ovarian, Sarcoma, Hodgkin Lymphoma
Intervention: Drug: PF-06801591
15 Not yet recruiting AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Other: Fluorothymidine F-18;   Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
16 Not yet recruiting A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: nivolumab
17 Recruiting Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Conditions: Diffuse Large B-cell Lymphoma (DLBCL);   Relapsed Diffuse Large B-cell Lymphoma (DLBCL);   Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Procedure: leukapheresis;   Drug: Plerixafor;   Drug: carmustine, etoposide, cytarabine, melphalan;   Procedure: Autologous Stem Cell Transplantation
18 Not yet recruiting Safety and Efficacy of Entospletinib (GS-9973) Combined With Vincristine (VCR) and VCR-based Combination Chemotherapy in Adult Participants With Non-Hodgkin Lymphoma (NHL)
Condition: Non-Hodgkin Lymphoma
Interventions: Drug: ENTO;   Drug: VCR;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Etoposide;   Drug: Filgrastim
19 Not yet recruiting Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Mediastinal Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions: Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
20 Recruiting A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity
Condition: Hodgkin Disease
Intervention: Drug: Brentuximab Vedotin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years